BioAtla, Inc. (BCAB)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about BioAtla, Inc. (BCAB)
Company Performance

Current Price

as of Oct 16, 2024

$1.96

P/E Ratio

N/A

Market Cap

$94.74M

Description

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Metrics

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBCAB
  • Price$1.96+0.51%

Trading Information

  • Market Cap$94.74M
  • Float80.70%
  • Average Daily Volume (1m)1,874,619
  • Average Daily Volume (3m)1,186,304
  • EPS-$2.18

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$21.07M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$21.74M
  • EV$6.05M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B3.02
Documents
SEC Filings
8-K (2024-09-23)
8-K (2024-08-08)
8-K (2024-06-13)
8-K (2024-05-17)
8-K (2024-05-14)
8-K (2024-04-24)
8-K (2024-03-26)
8-K (2024-02-21)
8-K (2024-02-12)
8-K (2024-01-09)
8-K (2024-01-08)
8-K (2023-12-13)
8-K (2023-12-04)
8-K (2023-11-07)
8-K (2023-08-01)
8-K (2023-06-14)
8-K (2023-05-11)
8-K (2023-03-23)
8-K (2023-03-10)
8-K (2023-02-27)
8-K (2023-02-15)
8-K (2023-01-06)
10-Q (2024-08-08)
10-Q (2024-05-14)
10-Q (2023-11-07)
10-Q (2023-08-01)
10-Q (2023-05-11)
10-K (2024-03-26)
10-K (2023-03-23)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: BioAtla Q3 (2023-11-08T13:47:28Z)
BioAtla reports Q3 net income ($33.3M) vs FactSet ($37.1M) [6 est, ($41.4)-(30.9M)] ($1.76, 0.00) (2023-11-07T21:48:43Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-12)
Earnings Report (2023-08-01)
Factset
Factset Business Description